4-[3,5-bis(1,1-dimethylpropyl)-4-hydroxyphenyl]-1,2-dithiole-3-thione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[3,5-bis(1,1-dimethylpropyl)-4-hydroxyphenyl]-1,2-dithiole-3-thione
• 英文别名: 4-[4-Hydroxy-3,5-bis(2-methylbutan-2-yl)phenyl]dithiole-3-thione
• 化学式: C₁₉H₂₆OS₃
• 分子量: 366.613
• InChiKey: LUDWENOTLKBFML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
  申请人：Patrick Prendergast

  公开号：US20040053989A1

  公开（公告）日：2004-03-18

  The invention provides methods to treat neurological disorders such as Alzheimer's disease, or to slow the progression of such diseases, or to treat and/or prevent other disorders as disclosed in the specification, by administering to patients, or delivering to the tissues of such patients, oltipraz or related compounds as disclosed in the specification.

  该发明提供了治疗神经系统疾病，如阿尔茨海默病的方法，或减缓这些疾病的进展，或治疗和/或预防其他疾病的方法，通过向患者或向这些患者的组织输送在规范中披露的oltipraz或相关化合物。
• COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM
  申请人：Prendergast, Patrick T.

  公开号：EP2026810A2

  公开（公告）日：2009-02-25
• COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS
  申请人：Prendergast, Patrick T.

  公开号：EP2134347A2

  公开（公告）日：2009-12-23
• Compositions and methods for modulating the immune system
  申请人：Prendergast Patrick T.

  公开号：US20090156546A1

  公开（公告）日：2009-06-18

  The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.
• Compositions and Methods for Preventing and Treating Mucositis and Weight Loss
  申请人：Cascade Estate Ltd.

  公开号：US20130259930A1

  公开（公告）日：2013-10-03

  Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia.